Dpp-4, inhibitor - Open Access .click

Results 191 to 200 of about 19,784 (215)

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, Volume 14, Issue 6, Page 1627-1635, September 2026.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan +3 more
wiley +1 more source

Immature Neutrophil Phenotype and Enhanced Myeloperoxidase in Male Patients With Chronic Kidney Disease and Cardiovascular Comorbidity

Acta Physiologica, Volume 242, Issue 9, September 2026.
ABSTRACT Aim Patients with chronic kidney disease (CKD) have an increased cardiovascular risk. Since neutrophils and neutrophil‐borne proteins contribute to cardiovascular disease, we analyzed the neutrophil phenotype in patients with CKD who presented with a spectrum of cardiovascular comorbidities.
Sonja Vondenhoff +22 more
wiley +1 more source

Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19

, 2020
Rhee SY, Lee J, Nam H, Kyoung D, Kim DJ.
europepmc +1 more source

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7791-7801, September 2026.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock +5 more
wiley +1 more source

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8057-8071, September 2026.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger +5 more
wiley +1 more source

Some of the next articles are maybe not open access.

Related searches:

diabetes mellitus
type 2 diabetes
dpp-4 inhibitor

dipeptidyl-peptidase iv inhibitors
dpp-4
therapeutics

pharmacology
diabetes mellitus, type 2
in silico

DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema

Journal of Investigative Medicine High Impact Case Reports, 2021
Chidinma Ejikeme
exaly

Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor

Mini-Reviews in Medicinal Chemistry, 2020
Ketan Hatware, Patil Kiran D, Sanjay Sharma +2 more
exaly

Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression

Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021
Michael Anthonius Lim, Arief Wibowo, Henny Juliastuti +2 more
exaly

The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies

Expert Opinion on Drug Safety, 2018
FRANCISCO J Tinahones +2 more
exaly